Literature DB >> 33522081

The promise of paediatric dolutegravir.

Rachel Golin1, Jeffrey M Samuel1, B Ryan Phelps1, Udita Persaud1, Christine Y Malati1, George K Siberry1.   

Abstract

Entities:  

Keywords:  HIV; antiretroviral therapy; children; dolutegravir; paediatric

Mesh：

Substances：

Year:  2021        PMID： 33522081      PMCID： PMC7848097          DOI： 10.1002/jia2.25660

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN： 1758-2652            Impact factor:   6.707


× No keyword cloud information.
  6 in total

Review 1.  Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.

Authors:  Bluma G Brenner; Mark A Wainberg
Journal:  Virus Res       Date:  2016-07-12       Impact factor: 3.303

2.  Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.

Authors:  Jean-Michel Molina; Bonaventura Clotet; Jan van Lunzen; Adriano Lazzarin; Matthias Cavassini; Keith Henry; Valeriv Kulagin; Naomi Givens; Carlos Fernando de Oliveira; Clare Brennan
Journal:  Lancet HIV       Date:  2015-03-10       Impact factor: 12.767

3.  Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules.

Authors:  Christine Y Malati; Rachel Golin; Lisa O'Brien; Nandita Sugandhi; Meena Srivastava; Chris Larson; Benjamin R Phelps
Journal:  J Int AIDS Soc       Date:  2019-04       Impact factor: 5.396

4.  Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

Authors:  Sharon Walmsley; Axel Baumgarten; Juan Berenguer; Franco Felizarta; Eric Florence; Marie-Aude Khuong-Josses; J Michael Kilby; Thomas Lutz; Daniel Podzamczer; Joaquin Portilla; Norman Roth; Deborah Wong; Catherine Granier; Brian Wynne; Keith Pappa
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-15       Impact factor: 3.731

5.  Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.

Authors:  Elaine J Abrams; Jintanat Ananworanich; Moherndran Archary; McNeil Ngongondo; Pim Brouwers
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

6.  Children and their families are entitled to the benefits of differentiated ART delivery.

Authors:  Lynne Wilkinson; George K Siberry; Rachel Golin; Benjamin R Phelps; Hilary T Wolf; Surbhi Modi; Anna Grimsrud
Journal:  J Int AIDS Soc       Date:  2020-04       Impact factor: 5.396
  6 in total
  3 in total

1.  Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots.

Authors:  Abdulafeez Akinloye; Oluwasegun Eniayewu; Babatunde Adeagbo; Oluseye Bolaji; Adeniyi Olagunju
Journal:  Ther Drug Monit       Date:  2022-06-01       Impact factor: 3.118

2.  The impact of the caregiver mobility on child HIV care in the Manhiça District, Southern Mozambique: A clinical based study.

Authors:  Tacilta Nhampossa; Sheila Fernández-Luis; Laura Fuente-Soro; Edson Bernardo; Arsenio Nhacolo; Orvalho Augusto; Ariel Nhacolo; Charfudin Sacoor; Anna Saura-Lázaro; Elisa Lopez-Varela; Denise Naniche
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

3.  Age-specific associations with dental caries in HIV-infected, exposed but uninfected and HIV-unexposed uninfected children in Nigeria.

Authors:  Vincent P Richards; Modupe O Coker; Paul Akhigbe; Nneka M Chukwumah; Morenike Oluwatoyin Folayan; Kimon Divaris; Ozoemene Obuekwe; Augustine Omoigberale; Elima Jedy-Agba; Michael Kim; Manhattan E Charurat
Journal:  BMC Oral Health       Date:  2022-09-27       Impact factor: 3.747
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.